Compare HSBC Holdings plc (HSBC) vs Viatris Inc (VTRS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
HSBC Holdings plc vs Viatris Inc — how do they compare? HSBC Holdings plc trades at $104.23 (market cap $353.82B), while Viatris Inc trades at $16.14 (market cap $18.69B). The key difference: HSBC Holdings plc is far larger — about 18.9× Viatris Inc's market cap, and HSBC Holdings plc pays the higher dividend (3.63%). Which is the better fit depends on your goals.
| HSBC | VTRS | |
|---|---|---|
Market Cap | $353.82B | $18.69B |
Sector | Technology | Health |
52-Week High | $107.86 | $17.86 |
52-Week Low | $63.84 | $9.49 |
Dividend Yield | 3.63% | 2.95% |
Enterprise Value | — | $30.80B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
HSBC trades at $104.05, up 0.71% today, with a bullish technical signal from moving averages and a P/E of 14.74. The bank reported strong Q2 2026 results, including a 7% revenue increase and a $1 billion buyback, while maintaining a 34.54% net income margin. Recent news highlights leadership changes and China-related market pressures.
Outlook remains positive due to earnings momentum and shareholder returns, but risks include China regulatory shifts and valuation concerns after a 40% run. Analyst consensus is mixed with 38% buy ratings, suggesting cautious optimism amid growth and external headwinds.
Viatris (VTRS) trades at $16.33, up 0.31% on the day, with a bearish technical signal despite recent earnings beats. The company reported Q2 2026 EPS of $0.69, exceeding expectations, and revenue growth of 5% year-over-year. However, negative net income margins and a high P/E ratio of 236.2 highlight profitability challenges. Recent developments include FDA approval for Gwyn Lo contraceptive patch and ongoing divestitures to sharpen focus.
Outlook remains mixed: operational improvements and dividend payments offer stability, but persistent net losses and high debt pose risks. Analyst consensus leans Hold (61.54%), reflecting cautious optimism amid execution uncertainties. Investment appeal hinges on successful margin recovery and debt management in a competitive generic drug market.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About HSBC Holdings plc
HSBC is one of the world's largest banking and financial services organizations. It serves customers worldwide through four global businesses: Retail, Commercial, Global Banking, and Private Banking.
Read more on HSBC →About Viatris Inc
Formed by the combination of Mylan and Pfizer's Upjohn business in 2020, Viatris is one of the world's largest generic drug manufacturers, with a substantial off-patent branded drug portfolio. Its portfolio consists of more than 1,400 molecules with penetration across most of the developed world and in select emerging markets. The company's branded drug portfolio consists of off-patent blockbuster drugs that continue to generate strong sales, including Lipitor, Norvasc, Lyrica, Viagra, and EpiPen. While global competition has facilitated the commodification of small-molecule generic drugs, the company has demonstrated an edge over peers in its ability to manufacture complex generics (for example, generic Advair and Copaxone).
Read more on VTRS →
